Status:
RECRUITING
Efficacy of Repetitive Transcranial Magnetic Stimulation Over the Primary Cortex in Patients With Neuropathic Pain and Cancer
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Cancer
Chronic Neuropathic Pain
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
High-frequency repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex (M1) has shown its efficacy to alleviate pain in patients suffering from refractory neuropathic pain. rTM...
Eligibility Criteria
Inclusion
- Patient affiliated to or entitled under a social security scheme
- Patient who has received informed information about the study and who has co-signed, with the investigator, a consent form to participate in the study.
- Patient aged 18 to 85 (male or female),
- Central or peripheral neuropathic pain related to cancer and/or its treatment;
- Chronic pain (present for more than 4 months) whose intensity is greater than or equal to 4/10 on a VAS (Visual Analogue Scale) numerical scale.
- Pain present on a daily or almost daily basis (at least 4 days a week)
- Patient not completely relieved by recommended first- and second-line drug treatments for neuropathic pain
- Stable analgesic treatment (no new treatment or dosage adjustment) for at least one month and will not need to be modified for the duration of the study.
- Patient can be followed throughout the study.
- Indication for rTMS of the motor cortex by a neurologist.
Exclusion
- Accident at work or litigation,
- Contraindication to rTMS or MRI (treatment with seismotherapy during the previous month; history of cranial trauma; intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulin pump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia).
- Chronic alcoholism
- Abuse of drugs or psychoactive substances
- Neuropathic pain as part of a progressive pathology (e.g. HIV),
- Presence of other pain of greater intensity than the neuropathic pain leading to inclusion
- Acute stroke (\< 3 months)
- Patient with brain tumour lesions
- Patient with infectious or metabolic brain lesions
- Patients with severe or recent cardiac disorders
- Patients with cognitive impairment
- Patient unable to understand informed consent,
- Patients refusing to stop or unable to stop treatments prohibited during the study, such as morphine.
- Patients participating in another research protocol involving a medicinal product within 30 days prior to inclusion.
- Patients deprived of their liberty or under legal protection (guardianship, curatorship, safeguard of justice, family habilitation).
Key Trial Info
Start Date :
June 13 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2029
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07187219
Start Date
June 13 2025
End Date
May 1 2029
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PEYRON Roland
Saint-Etienne, France, 42055